The voltage-gated Na v 1.5 channel is essential for the propagation of action potentials in the heart. Malfunctions of this channel are known to cause hereditary diseases. It is a prime target for class 1 antiarrhythmic drugs and a number of antidepressants. The purpose of the present study was to investigate the Na v 1.5 blocking properties of fluoxetine, a selective serotonin re-uptake inhibitor. Na v 1.5 channels were expressed in HEK-293 cells, and Na + currents were recorded using the patch-clamp technique. Doseresponse curves of racemic fluoxetine (IC 50 = 39 μM) and its optical isomers had similar IC 50 (40 and 47 μM for the (+) and (-) isomer, respectively). Norfluoxetine, a fluoxetine metabolite, had a higher affinity than fluoxetine, with an IC 50 of 29 μM. Fluoxetine inhibited currents in a frequency-dependent manner, shifted steady-state inactivation to more hyperpolarized potentials, and slowed the recovery of Na v 1.5 from inactivation.
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Introduction
Fluoxetine (Prozac) is a selective serotonin re-uptake inhibitor (SSRI) (Wong et al., 1995) that is widely prescribed for the treatment of Central Nervous System (CNS)-linked cognitive, emotional, and behavioral disorders. Since its discovery in 1974 (Wong et al., 1974) , the beneficial psychotropic effects of fluoxetine have led to its being used to treat disorders other than depression, including obsessive compulsive disorders (OCD) and bulimia nervosa (Wong et al., 1995) . The multiple side effects of fluoxetine (Sghendo and Mifsud, 2012) have raised questions about its supposed selective 5-HTmediated effect. While fluoxetine inhibits serotonin transporter (SERT) in the low nanomolar range (Torres et al., 2003) , its therapeutic effect appears only at a much higher plasma and brain concentrations (Muscettola et al., 1978; Bolo et al., 2000) . At low micromolar concentrations, fluoxetine also targets other proteins and inhibits several types of ion channels and receptors, including the nicotinic acetylcholine receptor (Hennings et al., 1999; Eisensamer et al., 2003) , voltage-gated Ca 2+ channels (Deák et al., 2000; Pacher et al., 2000) , volume-regulated anion channels (Maertens et al., 2002) , neuronal Na + channels (Lenkey et al., 2006) , and hERG, a cardiac K + channel (Thomas et al., 2002) . The inhibition of the hERG K + channel by fluoxetine occurs via two different mechanisms: (i) direct channel blockade and (ii) disruption of channel protein trafficking (Rajamani et al., 2006) . This may explain some of the cardiovascular side effects observed during chronic fluoxetine treatments, including bradycardia and QT prolongation (Pacher and Kecskemeti, 2008; Timour et al., 2012) . Dysfunctions of Na v 1.5, which are responsible for the rapid upstroke of the action potential caused by the rapid entry of Na + ions into cardiomyocytes, also lead to arrhythmia complications. The MOL #93104
5 prolongation of QT intervals may be due to the improper inactivation of the Na v 1.5 as in Romano-Ward syndrome (LQT3), while the reduction of Na + currents through Na v 1.5 may lead to arrhythmias such as Brugada syndrome (Herbert and Chahine, 2006) . The major cause of the higher mortality rate in psychiatric patients versus the general population is sudden cardiac death (SCD), which mainly results from arrhythmias that occur during treatments with psychotropic drugs. It has been reported that fluoxetine decreases the maximum rate of rise of the depolarization phase (V max ) of ventricular cell preparations (Pacher et al., 2000; Magyar et al., 2003) , but little is known about the direct effect of fluoxetine on the biophysical properties of Na v 1.5.
In the present study, we investigated the electrophysical properties of fluoxetine (racemic and enantiomers) and its metabolite norfluoxetine, as well as other psychotropic drugs, on Na v 1.5 stably expressed in HEK-293 cells. We showed that racemic fluoxetine, its metabolite norfluoxetine, and its enantiomers act as potential antagonists of human Na v 1.5 unlike the other classes of antidepressants tested.
We also studied the effect of the F1760C and Y1767C mutations of the class I antiarrhythmic binding site on the use-dependent blockade of cardiac Na + channels by fluoxetine and showed that fluoxetine behaves like a class I antiarrhythmic drug.
This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods
Cell cultures
Human embryonic kidney (HEK-293) cells stably expressing human Na v 1.5 were used as previously described (Huang et al., 2011) . In brief, the cells were grown under standard tissue culture conditions (5% CO 2 , 37°C) in high-glucose DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml of penicillin, and 10 mg/ml of streptomycin (Gibco-BRL Life Technologies, Burlington, ON). For experiments with the F1760C, Y1767C, and L409C/A410W mutants, the HEK-293 cells were transiently transfected with the pcDNA3.1 vector containing mutant Na v 1.5 cDNA (5 μg) or with the empty vector pIRES/CD8 (5 μg) in 10 cm petri dishes using the calcium phosphate method as previously described (Huang et al., 2011) . Transfected cells were briefly preincubated with CD8 antibody-coated beads (Dynabeads M450 CD8-a, (Life Technologies Inc., Burlington, ON, Canada) before recording currents. HEK-293 cells expressing the pIRES/CD8 vector were decorated with CD8 beads, which were used to identify cells for recording Na + currents.
Whole-cell patch-clamp recordings
Macroscopic Na + currents from HEK-293 cells were recorded using the whole-cell patchclamp technique. Patch-clamp recordings were obtained using low-resistance, fire- were filtered at 5 kHz, digitized at 10 kHz, and stored on a microcomputer equipped with an analog-to-digital converter (Digidata 1300, Molecular Devices). The cells were allowed to stabilize for 5 min after the whole-cell configuration was established before recording the currents. The experiments were performed at room temperature (22°C). The pipettes were filled with an intracellular solution composed of 35 mM NaCl, 105 mM CsF, 10 mM EGTA, and 10 mM Cs-HEPES. The pH was adjusted to 7.4 with CsOH.
The external solution was composed of 150 mM NaCl, 2 mM KCl, 1.5 mM CaCl 2 , 1 mM MgCl 2 , 10 mM glucose, and 10 mM HEPES. The pH was adjusted to 7.4 with NaOH.
The drugs were applied using a constantly running ValveLink8.2 ® gravity-driven perfusion system (Automate Scientific, Berkeley, CA) equipped with a glass syringe with a 250 µM tip. Different concentrations of the same drug were applied on the same cell.
We used silicone-free tubing since we had observed changes in fluoxetine concentrations when silicon tubing was used, most likely because fluoxetine adheres to silicone, which can change the applied concentrations considerably.
The peak current amplitudes at different drug concentrations were subtracted from the value obtained with the control solution and were normalized to the control value in order to obtain the dose-response curves and IC 50 values. Each point on the dose-response curves represents the mean of inhibition calculated from all recorded cells at a specific drug concentration. The values were fit to a Hill equation of the following form: is the concentration of agonist. To obtain activation curves, Na + conductance (G Na ) was calculated from the peak current (I Na ) using the following equation: G Na
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I Na /(V -E Na ), where V is the test potential and E Na is the reversal potential. Normalized G Na values were plotted against the test potentials. To obtain the inactivation curves, the peak current was normalized to the maximal value and was plotted against the conditioning pulse potential. Steady-state activation and inactivation curves were fit to a Boltzmann equation of the following form:
is the current, V 1/2 is the voltage at which the channels are half-maximally activated or inactivated, and
is the slope factor. To determine the recovery from inactivation, the test pulse peak current ‫ܫ(‬
) was normalized to the corresponding prepulse current
was plotted against the pulse interval and was fitted to a double or triple exponential function of the following form: The results were analyzed using a combination of pCLAMP software v10.2 (Molecular Devices), Microsoft Excel, and SigmaPlot v11.0 (SSPSS, Chicago, IL).
Statistical analysis
Results are expressed as means ± SEM. Statistical significance was calculated using Student's unpaired t test, and the level of statistical significance was set at P < 0.05. The
Drugs
Racemic fluoxetine, S (+) fluoxetine, S (-) fluoxetine, norfluoxetine, and (+) fenfluramine were from Sigma-Aldrich (St. Louis, MO). Nisoxetine and methylphenidate were from Tocris Bioscience (Bristol, UK). Stock solutions (5 mM) were prepared in water and were diluted in the external solution prior to use.
Homology modeling of fluoxetine binding site in the Na v 1.5
The human cardiac Na v 1. The alignment of bacterial Na v Ab and Na v Ms with eukaryotic sodium channels was taken as previously proposed (Payandeh et al., 2011; McCusker et al., 2012; Tikhonov and Zhorov, 2012 ). An insertion downstream from the DEKA locus was proposed (Tikhonov and Zhorov, 2012) , however, in our models, this insertion was not introduced This article has not been copyedited and formatted. The final version may differ from this version. and 5) because it is available in the X-ray structure. The extracellular linkers between Ploops and transmembrane helices were truncated to match the length of the X-ray structure templates, which does not affect ligand docking in the inner pore as they are distant. Ionizable residues were modeled as neutral, but the ionizable residues of DEKA locus were modeled as charged. S-fluoxetine was modeled as protonated, since its ammonium group has a pKa of ~10.
All calculations were performed using the ZMM program (www.zmmsoft.com, ZMM Software Inc., Flamborough, Ontario, Canada). The nonbonded energy was calculated using the AMBER force field (Weiner et al., 1984 (Weiner et al., , 1986 ) with a cutoff distance of 8 Å. Atomic charges at fluoxetine were calculated with the MOPAC software using the semi-empirical method AM1 (Dewar et al., 1985) . The hydration energy was calculated by using the implicit-solvent method (Lazaridis and Karplus, 1999 ).
Electrostatic energy was calculated using the environment-and distance-dependent dielectric function without desolvation energy (Garden and Zhorov, 2010) . The DEKA locus was loaded with an explicit water molecule, which was initially constrained to the Asp and Lys side chains, subsequently once constraints were removed, the water did not move away from the DEKA locus. The Monte Carlo minimization (MCM) method (Li and Scheraga, 1987) was used to optimize the models. All torsional angles of the protein and ligand were allowed to vary during energy calculations, while bond angles were rigid in the protein and flexible in the ligand. To prevent large deviations of the channel This article has not been copyedited and formatted. The final version may differ from this version.
models from the X-ray structure templates during energy minimizations, the α -carbons of the model were constrained to the template using a flat-bottom energy function that allows atoms to deviate penalty-free up to 1 Å, but imposes a penalty of 10 kcal mol -1 Å -1 for larger deviations. All molecular images were created using MVM. No specific energy terms were used for cation-π interactions, which were accounted for with partial negative charges at the aromatic carbons (Bruhova et al., 2008) .
The homology models were first MC-minimized without ligand until the 3000 consecutive energy minimizations did not improve the apparent global minimum found.
The optimal binding modes of S-fluoxetine were searched by a two-stage randomdocking approach. 
Results
Fluoxetine and its optical isomers block the Na v 1.5 channel
We studied the effect of fluoxetine on Na v 1.5 stably expressed in HEK-293 cells. Figure   1A shows an example of whole-cell current traces before (control) and after superfusion of 25 and 100 μM racemic fluoxetine. Fluoxetine inhibited Na + currents, with a maximum blockade occurring at 100 μM. The inhibition was partially reversible. The superfusion of increasing concentrations of fluoxetine (1, 10, 25, 50, 100, and 200 μM) showed that the blockade by fluoxetine was dose dependent. The dose-response curves ( Effect of fluoxetine on the steady-state gating properties of Na v 1.5 channels
The availability of Na + channels following depolarization depends on a number of parameters, including the membrane potential. Fewer channels become available as the membrane potential progressively becomes more depolarized. This is due to the buildup of channels in the inactivated non-conducting state. We studied this phenomenon using a double-pulse protocol: a 500 ms conditioning pulse to voltages ranging from -140 mV to 0 mV, and a test pulse to -30 mV. The current measured following the test pulse is an indicator of the fraction of available channels. The normalized currents following the test pulse were plotted against the conditioning voltage ( Fig. 2A ). Fluoxetine (30 μM)
significantly shifted the V 1/2 of inactivation of Na v 1.5 by 6.7 mV toward more hyperpolarized voltages and resulted in a less steep slope factor (Table 1 and Fig. 2A ).
We also investigated the effect of fluoxetine on the steady-state activation of Na v 1.5.
The activation curves were derived from I/V curves (see Materials and Methods). The activation curves of Na v 1.5 in the absence and presence of 30 μM fluoxetine were plotted against voltage ( Fig. 2A ). Fluoxetine did not significantly shift the midpoint of steadystate activation but had a little effect on the slope factor by reducing its steepness.
Fluoxetine slows the recovery from inactivation of Na v 1.5 channels
A prominent characteristic of many class 1 antiarrhythmics is their ability to slow the recovery from inactivation of drug-modified Na + channels. We used a two-pulse protocol This article has not been copyedited and formatted. The final version may differ from this version. to investigate the effect of fluoxetine on the recovery from inactivation. We used a 40 ms, -30 mV conditioning pulse and a 20 ms, -30 mV test pulse, with an interval ranging from 0.1 to 4000 ms to induce recovery from inactivation. The amplitudes of the Na + currents measured following the test pulse were then normalized to the control currents and were plotted against the duration of the recovery interval. Channels that recovered from inactivation displayed a progressive increase in currents following the increase in the recovery interval (Fig. 2B ). The recovery from inactivation of Na v 1.5 after fluoxetine treatment was strongly slowed with the appearance of a third time constant. In comparison, the control curve had a τ 1 and τ 2 of 1.50 and 9.13 ms, respectively, while the fluoxetine had a τ 1 , τ 2 and τ 3 of 1.63, 14.90 and 1598.23 ms, respectively (Table 1) .
Fluoxetine blocks Na v 1.5 channels in a use-dependent manner
During depolarization, Na + channels cycle from the resting to the activated and inactivated states. However, when they are subjected to a train of depolarizing pulses, the number of channels available to open is reduced because they are gradually trapped in the inactivated state. This phenomenon is referred to as use-dependence or "frequencydependent" current reduction. In the presence of a drug, further decreases in currents are likely due to the accumulation of drug-modified channels. For example, lidocaine, a class 1 antiarrhythmic drug, is known to cause the use-dependent inhibition of Na + channels.
We tested the effect of rapid pulsing on Na v 1.5 by applying a series of 50 short 10 ms depolarizing -30 mV pulses. We first characterized the effect of fluoxetine on Na v 1.5/WT, and then on the Na v 1.5/F1760C and Na v 1.5/Y1767C mutant channels. We previously reported that these highly conserved residues of the D4S6 directly contribute This article has not been copyedited and formatted. The final version may differ from this version. Figure 3A , in the absence of fluoxetine, there was no significant change in the availability of Na v 1.5/WT channels when they were pulsed up to 10 Hz. However, in the presence of 30 μM fluoxetine, the availability of Na v 1.5/WT channels was dramatically reduced by 44% (P50/P1) when they were pulsed at 2 Hz (Fig. 3B-C) in comparison with the control without drug. When 5 and 10 Hz pulses were used, 30 μM fluoxetine reduced the currents of the Na v 1.5/WT by 58% and 67%, respectively compared to the control without drug. To further investigate the role of class 1 antiarrhythmic binding in the current block caused by fluoxetine, we inserted the F1760C or Y1767C mutation into Na v 1.5. As shown in Figure 3B -C, 30 μM fluoxetine reduced the current by 8%, 15%, and 20% when Na v 1.5/F1760C were pulsed at 2, 5, and 10 Hz, respectively, in comparison with the control without drug. The Y1760C mutation almost completely prevented the use-dependent inhibition of fluoxetine, with a maximal current inhibition of 5% when pulsed at 10 Hz. These results indicated that fluoxetine blocks Na v 1.5/WT currents in a use-dependent manner, and that the F1760C and Y1767C mutations dramatically reduce the use-dependent inhibition.
Fluoxetine had a lower affinity for Na v 1.5/F1760C mutant channels
We studied the effect of the F1760C and Y1767C mutations on the concentrationdependent block of Na v 1.5 currents by fluoxetine. Figure 4A shows examples of current traces recorded from Na v 1.5/WT and the mutant channels before and after a treatment with 50 μM fluoxetine. As shown in Figure 4B , while the IC 50 value of fluoxetine for This article has not been copyedited and formatted. The final version may differ from this version. Na v 1.5/Y1767C (50.1 μM) was slightly higher to that of Na v 1.5/WT (39.4 μM), the IC 50 value for Na v 1.5/F1760C (82.8 μM) was more than twice that of the WT channel.
Fluoxetine act as an open-channel blocker
To investigate the role of inactivation in the blockade of Na v 1.5 by fluoxetine in greater detail, we used Na v 1.5/L409C/A410W mutant stably expressed in HEK-293 cells. These channels exhibit a significant reduction in fast inactivation in HEK-293 (Wang et al., 2013) . A large persistent current was detected in the absence of fluoxetine (Fig. 5A ). We applied different concentrations of fluoxetine and determined the IC 50 at the peak current and at the end of the test pulse (90-100 ms). The block at the end of the pulse represents the affinity of the fluoxetine for open channels. As shown in Figure 5B , the IC 50 (3.5 μM)
at the end of the pulse was slightly lower than the IC 50 at the peak current (9.6 μM),
suggesting that fluoxetine is an open-channel blocker.
Molecular modeling of fluoxetine in the Na v 1.5
To discover the molecular details of the fluoxetine binding site, we have homology modeled the pore domain of the cardiac Na v 1.5 in the closed and open states based on the X-ray structures of bacterial Na channels, Na v Ab (Arcobacter butzleri sodium channel) (Payandeh et al., 2011) and Na v Ms (Magnetococcus sp sodium channel) (Bagnéris et al., 2013) , respectively (see PDB file in Data Supplement). A random sampling approach was used to search for the energetically most favorable binding modes of fluoxetine in the Na v 1.5. 60 000 random orientations of fluoxetine were seeded inside the channel within a volume to cover the entire pore cavity and inner helix interfaces (Fig. 6A, B) . After two Further, the backbone carbonyl groups of residues two to three positions upstream of the DEKA locus (positions p47 and p48) also stabilize fluoxetine.
The horizontal and vertical binding modes are distinguished by the two benzene arms of fluoxetine. In the vertical binding mode (Fig. 6 C, E), one benzene arm is parallel and the other arm is perpendicular to the pore axis. In this mode, one benzene ring π -stacks with Y 4i22(1767) and the other interacts with F 4i15 (1760) . Y 4i22 and F 4i15 were found to be the two most significant residues in binding fluoxetine; each contributes 16-33% to the ligand-receptor energy. In the horizontal binding mode (Fig. 6 D, F) , the two benzene suggesting that F1760 and Y1767 are the two key residues for its binding.
Discussion
In the present study, we characterized the effects of fluoxetine, a widely used antidepressant drug, on Na v 1.5, the cardiac voltage-gated Na + channel.
Our results showed that racemic fluoxetine and its optical isomers are equally effective blockers of Na v 1.5 when current were recorded at a holding potential of -140 (Magyar et al., 2003) . We also conducted dose-response curves experiments for racemic fluoxetine in HEK-293 at a holding potential of -90 mV, which is near the resting potential of cardiomyocytes. These experiments showed that the IC 50 of fluoxetine is eight time lower at a holding potential of -90 mV compared to -140 mV, going from 39.4
μM to 4.7 μM. In a manner that is hard to explain, these data are in contradiction with those published by Rajamani et al. who reported that fluoxetine does not inhibit Na been also shown in rat hippocampi neurons (Lenkey et al., 2006) , suggesting that the fluoxetine binds with higher affinity to inactivated than to resting channels.
In the nervous system, fluoxetine primary targets SERT, which, together with dopamine transporter (DAT) and norepinephrine transporter (NET), make up the three major MAT classes. In order to investigate the effect of other MAT-targeting drugs, we investigated the effect of nisoxetine (NET-targeting drug) (Tejani-Butt, 1992), methylphenidate (DAT-targeting drug) (Han and Gu, 2006) , and fenfluramine (SERTtargeting drug) (Cosgrove et al., 2010) on Na v 1.5 currents. Our results showed that the affinity of these drugs for Na v 1.5 is dependent of the holding potential. The IC 50 of nisoxetine, methylphenidate and fenfluramine are respectively 5, 2.5 and 3 times lower at a holding potential of -90 mV compared to -140 mV. Like the fluoxetine, the decrease of This article has not been copyedited and formatted. The final version may differ from this version. IC 50 at more depolarized potential suggests a higher affinity of these three compounds to inactivated than to resting channels. Furthermore, these compounds also exhibited a usedependent inhibition, especially nisoxetine with a significant current reduction of 26%, 36% and 38% when pulsing at 2, 5 and 10 Hz, respectively (data not shown). However, these three compounds are still less potent than fluoxetine to inhibit Na v 1.5.
The present study was designed to investigate the biophysical mechanism of the Na v 1.5 block by fluoxetine as well as the possible pro-arrhythmic properties of this drug.
A major finding of our work was that fluoxetine shifts the steady-state inactivation curve by 6.7 mV toward more hyperpolarized values, indicating that it binds to the inactivated state of Na v 1.5, as is the case with neuronal Na + channels (Lenkey et al., 2006) . In addition to a tonic block, fluoxetine decreased Na v 1.5 currents in a use-dependent manner when pulsing at 2, 5 and 10 Hz, The affinity of fluoxetine for Na v 1.5 thus appears to be modulated by the state of the channel, which rapidly switches between the open and inactivated configurations, leading to the progressive accumulation of inactivated Na v 1.5.
Use-dependence occurs because drug-modified channels slowly recover only at hyperpolarized voltages. Class 1 antiarrhythmic drugs and local anesthetics have a similar effect (Chahine et al., 1992) . We thus determined whether fluoxetine could inhibit Na + currents by mutating residues in the class 1 antiarrhythmic drug binding site. Amino acids situated near the cytoplasmic ends of the membrane-spanning S6 α-helixes of all four homologous domains (D1S6-D4S6) form the cytoplasmic entrance of the pore and contribute to the binding sites of both the native inactivation gate and class 1 antiarrhythmic drugs. We previously reported that two highly conserved residues of the D4S6 segment (F1760, Y1767) contribute directly to the local anesthetic binding site of This article has not been copyedited and formatted. The final version may differ from this version. Structurally, fluoxetine resembles most classical local anesthetics in approximate size and by possessing an ammonium group and a benzene ring. Fluoxetine adopts similar binding modes in the closed channel homology model as QX-314, cocaine, and tetracaine (Bruhova et al., 2008; Tikhonov and Zhorov, 2012) . Since fluoxetine can protrude between the III-IV inner helix interface while in the horizontal binding mode, it could This article has not been copyedited and formatted. The final version may differ from this version. suggest that fluoxetine may enter or exit through the III-IV domain interface pathway from the extracellular side of the membrane as it has been demonstrated with local anesthetics (Qu et al., 1995; Sunami et al., 2001) . Experiments with fluoxetine with a quaternarized ammonium could reveal whether the ligand can block from the extracellular side.
The blockade of the Na v 1.5 by fluoxetine should be taken into consideration when prescribing this drug. Blocking the cardiac Na + channel may cause an intracardiac conduction delay, which may in turn cause a prolongation of the QRS complex on the electrocardiogram (Delk et al., 2007) . Given the association between QRS prolongation and mortality, and the potential for drug-induced arrhythmia, caution is required when prescribing fluoxetine (Thanacoody and Thomas, 2005; Delk et al., 2007) , especially
given that inhibiting the Na v 1.5 by as little as 10% may cause a prolongation of the QRS complex in humans (Cordes et al., 2009 ). However, a question remains as to how to transpose the significance of the IC 50 value of fluoxetine to a pathophysiological setting.
The IC 50 /fC max ratio, where fC max represents the unbound (free) plasma concentration in a clinical setting, of a drug that evokes a QRS or a change in QT has been proposed as a tool for determining whether a drug can be safely prescribed (Redfern et al., 2003; Harmer et al., 2011 ). An IC 50 /fC max ratio above 30 to 100 has been shown to ensure a suitable degree of safety in terms of drug-induced QRS complex prolongation. The fC max for fluoxetine is 93 nM (Harmer et al., 2011) . Thereby, when we mimic the membrane potential of cardiomyocytes in patch-clamp by imposing a holding potential of -90 mV to HEK-293 cells, the IC 50 /fC max ratio is 50. This is within the 30 to 100 margin and it should act as a safety flag for a possible cardiotoxicity.
This article has not been copyedited and formatted. The final version may differ from this version. Furthermore, in the case of fluoxetine, fC max may not be a good indicator of actual plasma concentrations of total Na v 1.5 blockers in vivo since norfluoxetine, an active metabolite of fluoxetine, has a higher affinity for Na v 1.5 than fluoxetine itself. Given that norfluoxetine has a half-life of more than a week compared to 70 h for a single dose of fluoxetine (Schepens, 1996) , there is a possibility of a long-lasting additive effect on cardiac Na + channels. In fact, in the calculation of the IC 50 /fC max ratio, we should take into consideration the unbound (free) plasma concentration of norfluoxetine. Despite the lack of information about the fC max after a single dose, it is known that the plasma concentration of total (unbound and bound) fluoxetine and norfluoxetine at steady state are very similar after chronicle treatment (91 to 302 ng/ml and 72 to 258 ng/ml, respectively) (U.S. Food and Drug Administration). These suggest that the IC 50 /fC max ratio following fluoxetine treatment is probably underestimated.
In conclusion, caution should be taken when prescribing fluoxetine at same time as other Na + channel inhibitors such as class 1 anti-arrhythmic drugs, especially class 1A and 1C drugs. In addition, fluoxetine should be prescribed with extreme care for patients suffering from ventricular conduction disorders or liver disease. Indeed, as the liver is the primary site of fluoxetine metabolism, its impairment, such cirrhosis, affects the elimination half-life of fluoxetine and norfluoxetine (Schenker et al., 1988) .
Figure 2
Gating properties of Na v 1.5/WT treated with fluoxetine. (A) Voltage-dependence of steady-state activation and inactivation of Na v 1.5. Cells were perfused with Ringer's solution as a control (activation, n = 14; inactivation, n = 19) or with 30 µM racemic fluoxetine (activation, n = 18; inactivation, n = 17). Activation curves were elicited with 50 ms depolarizing steps from -100 to 80 mV in 10 mV increments. Cells were held at a holding potential of -140 mV. Fluoxetine caused no significant shift in the activation curve. Steady-state inactivation was determined using 4 ms test pulses to -30 mV after a 500 ms prepulse to potentials ranging from -140 mV to 0 mV (see the inset under the inactivation curves for the protocol). The application of 30 µM fluoxetine induced a significant -6.7 mV shift of the inactivation curve (***P < 0.001) ( Table 1) The application of 30 µM fluoxetine strongly slowed the recovery from inactivation with the appearance of a third time constant (Table 1) .
This article has not been copyedited and formatted. The final version may differ from this version. 5 Hz, and 10 Hz. Peak currents were measured, normalized to the peak amplitude at P 1 , and plotted against the corresponding pules. (C) Relative currents amplitudes (P 50 /P 1 ) of the 50th sweep recorded from Na v 1.5/WT, Na v 1.5/F1760C and Na v 1.5/Y1767C. After the fluoxetine treatment, Na v 1.5/WT (n = 8) currents were significantly reduced by 44%, 58%, and 67% compared to the control when pulsing at 2, 5, and 10 Hz, respectively ( * * * P < 0.001). Fluoxetine significantly reduced Na v 1.5/F1760C (n = 11) currents by 15% and 20% when pulsing at 5 and 10 Hz (###P < 0.001), respectively, and Na v 1.5/Y1767C (n = 6) currents by 5% when pulsing at 10 Hz (ϕ ϕ P < 0.01) compared with control. There was no significant use-dependent inhibition of Na v 1.5/WT (n = 7), Na v 1.5/F1760C (n = 5), or Na v 1.5/Y1767C (n = 6) currents before the fluoxetine treatment. The controls curves of Na v 1.5/WT, Na v 1.5/F1760C and Na v 1.5/Y1767C without fluoxetine treatment were removed from the graphic B and C for clarity. values of Na v 1.5/F1760C (83 μM) and Na v 1.5/Y1767C (50 μM) were significantly higher than Na v 1.5/WT value (39 µM), * * P < 0.01 and * * * P < 0.001. The different concentrations of drugs were applied using a perfusion system. Currents were elicited from a holding potential of -140 mV with a 50 ms test pulse at -30 mV delivered every 5
s. Insets in B shows the IC 50 for each compound. Normalized current (I Na ) values were fitted to a Hill equation.
Figure 5
Open-channel block of Na Dose-response curves of the inhibitory effect of fluoxetine on Na v 1.5/L409C/A410W at the peak current (blue circle) and 90-100 ms after the beginning of the pulse (green square). The IC 50 value at the end of the pulse (3.5 μM) was significantly lower than the IC 50 value at the peak current (9.6 μM) ( * * * P < 0.001). Currents were elicited from a holding potential of -140 mV with a 50 ms test pulse at 0 mV delivered every 5 s.
Normalized current (I Na ) values were fitted to a Hill equation. Dotted grey boxes represent the peak current (left boxe) and the 90-100 ms (right boxe) areas used to construct the dose-response curves.
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